Ardelyx (ARDX) Other Non-Current Assets (2013 - 2026)
Ardelyx (ARDX) reported Other Non-Current Assets of $6.7 million for Q1 2026, down 2.02% on a YoY basis from $6.8 million in Q1 2025, and down 3.63% quarter-over-quarter from $6.9 million in Q4 2025.
Ardelyx (ARDX) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Ardelyx has reported Other Non-Current Assets for 14 years, with the latest figure at $6.7 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 2.02% year-over-year to $6.7 million; the trailing twelve-month figure through Mar 2026 stood at $6.7 million (down 2.02% YoY), and the FY2025 full-year result was $6.9 million, up 28.06% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $6.7 million, down from $6.9 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $13.3 million in Q3 2022, with the low at $673000.0 in Q2 2023.
- Historically, Other Non-Current Assets has averaged $4.9 million across 5 years, with a median of $5.4 million in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 976.01% — and 2023, when it plunged 88.36%.
- Ardelyx's Other Non-Current Assets stood at $881000.0 in 2022, then jumped by 308.17% to $3.6 million in 2023, then jumped by 50.61% to $5.4 million in 2024, then rose by 28.06% to $6.9 million in 2025, then retreated by 3.63% to $6.7 million in 2026.
- The last three Other Non-Current Assets figures came in at $6.7 million (Q1 2026), $6.9 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | 6.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.68 Mn |
| Dec 31, 2025 | 6.94 Mn |
| Sep 30, 2025 | 6.78 Mn |
| Jun 30, 2025 | 7.07 Mn |
| Mar 31, 2025 | 6.82 Mn |
| Dec 31, 2024 | 5.42 Mn |
| Sep 30, 2024 | 5.33 Mn |
| Jun 30, 2024 | 5.45 Mn |
| Mar 31, 2024 | 5.50 Mn |
| Dec 31, 2023 | 3.60 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Jun 30, 2023 | 673,000.00 |
| Mar 31, 2023 | 774,000.00 |
| Dec 31, 2022 | 881,000.00 |
| Sep 30, 2022 | 13.32 Mn |
| Jun 30, 2022 | 4.91 Mn |
| Mar 31, 2022 | 1.23 Mn |
| Dec 31, 2021 | 1.15 Mn |
| Sep 30, 2021 | 1.24 Mn |
| Jun 30, 2021 | 1.31 Mn |